In Wednesday’s Wall Street session, Gilead Sciences, Inc (NASDAQ:GILD) shares traded at $108.00, unchanged from the previous session.
GILD stock price is now 2.02% away from the 50-day moving average and 10.68% away from the 200-day moving average. The market capitalization of the company currently stands at $134.34B.
On March 04, 2025, Oppenheimer reiterated its ‘Outperform’ rating on the stock by increasing its target price from $115 to quote $132, while ‘Deutsche Bank’ rates the stock as ‘Buy’
In other news, Dickinson Andrew D, Chief Financial Officer sold 2,500 shares of the company’s stock on Jun 16 ’25. The stock was sold for $275,425 at an average price of $110.17. Upon completion of the transaction, the Chief Financial Officer now directly owns 165,110 shares in the company, valued at $17.83 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jun 16 ’25, Chief Commercial Officer Mercier Johanna sold 3,000 shares of the business’s stock. A total of $330,510 was realized by selling the stock at an average price of $110.17. This leaves the insider owning 120,168 shares of the company worth $12.98 million. A total of 0.16% of the company’s stock is owned by insiders.
During the past 12 months, Gilead Sciences, Inc has had a low of $62.69 and a high of $119.96. As of last week, the company has a debt-to-equity ratio of 1.30, a current ratio of 1.37, and a quick ratio of 1.23. The fifty day moving average price for GILD is $105.8602 and a two-hundred day moving average price translates $97.58055 for the stock.
The net profit margin was 20.79% and return on equity was 32.51% for GILD. The company reported revenue of $6.67 billion for the quarter, compared to $6.69 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -0.28 percent.
